潤貝航科(001316.SZ):已佈局國產化航材生產基地,建成後將大幅提高國產化航材規模化製造能力
格隆匯11月23日丨潤貝航科(001316.SZ)於近期進行投資者關係活動,就“請談談公司在自研航材自主製造領域的佈局”,公司回覆稱,公司已佈局國產化航材生產基地,建成後將大幅提高國產化航材規模化製造能力。公司的首發上市募投項目之一廣東潤和新材料公司航空非金屬材料、複合材料、航空清潔用品生產基地新建項目實施主體為公司子公司潤和新材料,目前項目已完成驗收和設備採購,處於後期的裝修和設備調試階段,未來將用於生產國產化航空精細化工產品、航空特種膠帶、PMA件和電子件;公司控股子公司杭州輕雲將主要負責航空、航天先進複合材料的研發、生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.